Clinical value of cancer stem cell markers in colorectal cancer

Timothy James Miller

Research output: ThesisDoctoral Thesis

Abstract

Cancer stem-like cells (CSC) are a sub-population of tumour cells that are self-renewing, chemoresistant and highly tumourigenic. A number of markers that identify CSC have shown promise as clinically useful tools in colorectal cancer (CRC). This thesis investigated the relevance of CSC marker expression during disease progression, chemotherapy response and survival in patients with CRC. It was found that increased expression of the pluripotency-associated transcription factor SOX2 in patients' tumours was associated with reduced response to chemotherapy and poor survival outcomes. SOX2 may therefore provide a potential target for anti-CSC therapies, which could improve response and survival rates in CRC.
LanguageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
Supervisors/Advisors
  • Platell, Cameron, Supervisor
  • McCoy, Melanie, Supervisor
  • Iacopetta, Barry, Supervisor
Thesis sponsors
Award date15 Feb 2018
DOIs
StateUnpublished - 2018

Fingerprint

Neoplastic Stem Cells
Colorectal Neoplasms
SOXB1 Transcription Factors
Drug Therapy
Survival
Cell- and Tissue-Based Therapy
Disease Progression
Neoplasms
Survival Rate
Population

Cite this

@phdthesis{f55918a0e8004cceaa1a38ab22b77db7,
title = "Clinical value of cancer stem cell markers in colorectal cancer",
abstract = "Cancer stem-like cells (CSC) are a sub-population of tumour cells that are self-renewing, chemoresistant and highly tumourigenic. A number of markers that identify CSC have shown promise as clinically useful tools in colorectal cancer (CRC). This thesis investigated the relevance of CSC marker expression during disease progression, chemotherapy response and survival in patients with CRC. It was found that increased expression of the pluripotency-associated transcription factor SOX2 in patients' tumours was associated with reduced response to chemotherapy and poor survival outcomes. SOX2 may therefore provide a potential target for anti-CSC therapies, which could improve response and survival rates in CRC.",
keywords = "Colorectal cancer, Cancer stem cells, immune cells, SOX2, FoxP3, PD-L1, CD133",
author = "Miller, {Timothy James}",
year = "2018",
doi = "10.4225/23/5a98e48209780",
language = "English",
school = "The University of Western Australia",

}

Miller, TJ 2018, 'Clinical value of cancer stem cell markers in colorectal cancer', Doctor of Philosophy, The University of Western Australia. DOI: 10.4225/23/5a98e48209780

Clinical value of cancer stem cell markers in colorectal cancer. / Miller, Timothy James.

2018.

Research output: ThesisDoctoral Thesis

TY - THES

T1 - Clinical value of cancer stem cell markers in colorectal cancer

AU - Miller,Timothy James

PY - 2018

Y1 - 2018

N2 - Cancer stem-like cells (CSC) are a sub-population of tumour cells that are self-renewing, chemoresistant and highly tumourigenic. A number of markers that identify CSC have shown promise as clinically useful tools in colorectal cancer (CRC). This thesis investigated the relevance of CSC marker expression during disease progression, chemotherapy response and survival in patients with CRC. It was found that increased expression of the pluripotency-associated transcription factor SOX2 in patients' tumours was associated with reduced response to chemotherapy and poor survival outcomes. SOX2 may therefore provide a potential target for anti-CSC therapies, which could improve response and survival rates in CRC.

AB - Cancer stem-like cells (CSC) are a sub-population of tumour cells that are self-renewing, chemoresistant and highly tumourigenic. A number of markers that identify CSC have shown promise as clinically useful tools in colorectal cancer (CRC). This thesis investigated the relevance of CSC marker expression during disease progression, chemotherapy response and survival in patients with CRC. It was found that increased expression of the pluripotency-associated transcription factor SOX2 in patients' tumours was associated with reduced response to chemotherapy and poor survival outcomes. SOX2 may therefore provide a potential target for anti-CSC therapies, which could improve response and survival rates in CRC.

KW - Colorectal cancer

KW - Cancer stem cells

KW - immune cells

KW - SOX2

KW - FoxP3

KW - PD-L1

KW - CD133

U2 - 10.4225/23/5a98e48209780

DO - 10.4225/23/5a98e48209780

M3 - Doctoral Thesis

ER -